Cytrx Corp (NASDAQ:CYTR)

CAPS Rating: 2 out of 5

A biopharmaceutical research and development company engaged in developing human therapeutic products based primarily upon its small molecule molecular chaperone co-induction technology.

Recs

0
Player Avatar StockRakedotcom (< 20) Submitted: 10/8/2007 1:33:58 PM : Outperform Start Price: $22.40 CYTR Score: -73.89

Bought today.

Featured Broker Partners


Advertisement